Dr Simon Hughes

Dr Simon Hughes is Consultant Clinical Oncologist at Guy's and St Thomas' NHS Foundation Trust, and an Honorary Senior Lecturer at King's College London School of Medical Education (GKT Medical School). He specialises in the treatment of Urological cancers: Bladder Cancer, Prostate Cancer and Radiotherapy for other Urological Cancers. Simon Hughes trained at Guy's and St Thomas' Hospitals Medical School, where he also gained a BSc with First Class honours (Anatomy). His specialist training in Clinical Oncology included posts at The Middlesex Hospital, University College London Hospitals, and Guy's & St. Thomas' Hospitals. He also spent over 2 years working in the Imaging Sciences Laboratories at Kings College London, and the Centre for Medical Image Computing at University College London developing novel radiotherapy techniques for the treatment of mobile tumours.

Simon continues to have an active role in Research and Development. He led the Clinical Oncology and Radiotherapy Research and Development Team at Guy's and St. Thomas' Hospitals for 5 years, and was also Radiotherapy Clinical Trials Lead for the South East London Cancer Network during this period. His research interests include tumour motion, radiotherapy dose escalation, integration of functional imaging into radiotherapy planning, and the combination of novel agents with radiotherapy. He is the UK lead for the ENZARAD Study, and is a member of several Trial Management Groups / Data Monitoring Committees. Simon's other main interest is medical education. He is the Education and Training Lead for King's Health Partners Comprehensive Cancer Centre; an Associate Clinical Dean at King's College London School of Medical Education; and is the Clinical Education and Training Lead for King's College London School of Cancer and Pharmacological Sciences. Nationally, Simon is the Treasurer for the British Uro-oncology Group; and was the co-opted oncologist for the British Association of Urological Surgeons: Oncology Section Committee from 2013-2017. He is also a past President of the Oncology Section of the Royal Society of Medicine (2011-2012), and served on council for over 10 years.

• Bladder Cancer
• Prostate Cancer
• Radiotherapy for other Urological Cancers
• SABR / Cyberknife (for Urological Cancers)
• Radionuclide Therapy (for Urological Cancers)

• Bladder Cancer
• Prostate Cancer
• Radiotherapy for other Urological Cancers
• SABR / Cyberknife (for Urological Cancers)
• Radionuclide Therapy (for Urological Cancers)